Kamada (KMDA)

5.230
-0.040(-0.76%)
  • Volume:
    4,703
  • Bid/Ask:
    5.190/5.240
  • Day's Range:
    5.200 - 5.237

KMDA Overview

Prev. Close
5.27
Day's Range
5.2-5.237
Revenue
-
Open
5.23
52 wk Range
5.11-8.849
EPS
-
Volume
4,703
Market Cap
236.5M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
41,392
P/E Ratio
13.66
Beta
-
1-Year Change
-33.71%
Shares Outstanding
44,745,364
Next Earnings Date
Nov 15, 2021
What is your sentiment on Kamada Ltd?
or
Vote to see community's results!

Kamada Ltd News

  • Stocks to watch next week
    • BySeeking Alpha-

    Key events are scheduled for the companies listed below next week. Notable earnings reports: Tyson Foods (NYSE:TSN), Progressive (NYSE:PGR), and Kamada (NASDAQ:KMDA) on...

  • Stocks to watch next week
    • BySeeking Alpha-

    Key events are scheduled for the companies listed below next week. Notable earnings reports: Hasbro (NASDAQ:HAS), Kimberly-Clark (NYSE:KMB) on October 23; McDonald's (NYSE:MCD),...

  • Kamada announces CFO transition
    • BySeeking Alpha-

    Kamada (NASDAQ:KMDA) announces that Gil Efron, Deputy CEO & CFO, will leave the Company at the end of the year. Chaime Orlev, will succeed him as CFO, effective January 1,...

Kamada Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyStrong SellStrong Sell
Technical IndicatorsNeutralSellNeutralStrong SellStrong Sell
SummaryBuyNeutralNeutralStrong SellStrong Sell

Kamada Ltd Company Profile

Kamada Ltd Company Profile

Employees
408
Market
Israel

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Read More
  • MERCATOR  WA [MRCP] The leader in Europe with no debt and with ridiculous low PE about 4 after Q4 2020 report
    0
    • FDA APPROVAL SEASON: COVID-19 VERSION LIMITED ESITIONAfter Gilead’s approval, Surely there’ll be a wave of approvals in the vaccine related companies.
      0
      • There we go! 😍
        0
        • There are very big hopes here, treatment for Covid already working! question of time for 300% up!
          0
          • Go home to sleep
            2
        • down, down, down
          1
          • all over the world, shares will be falling
            0
            • boom tomorrow to the moon's 100$!!
              2
              • I saw the news but is it going to happen for sure? Are you experienced?
                1
              • Mohammad Alazzah sell on news
                1
              • Buy thr rumor and sell the news makes sense. Thanks
                0
            • daytrippers cause revenue harvest now but Kamd has stronger future
              0
              • why is it falling?
                0
                • One person was dead after treatment, but reason of the death not approved yet.
                  0
              • They should be releasing a test soon
                0
                • Kamada is a good company an I have great belief in the management and her products
                  0
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.